James Bukuts, MD
Psychiatry · Cleveland, OHNPI 1518055813
Payments from drug & device makers
Across 11 payments — averaging $559.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$6K
- Axsome Therapeutics, Inc.$123
- Otsuka America Pharmaceutical, Inc.$119
- Vanda Pharmaceuticals Inc.$22
- TMS Neurohealth Centers Inc.$16
- AbbVie$15
- plus $28 from 2 others
What the payments were for
- Speaking & faculty fees$5,70093%
- Food & beverage$4577%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 4 | $5,835 |
| Axsome Therapeutics, Inc. | 1 | $123 |
| Otsuka America Pharmaceutical, Inc. | 1 | $119 |
| Vanda Pharmaceuticals Inc. | 1 | $22 |
| TMS Neurohealth Centers Inc. | 1 | $16 |
| AbbVie | 1 | $15 |
| Johnson & Johnson | 1 | $15 |
| Sunovion Pharmaceuticals Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$23,300
- ARISTADA INITIO$5,825
- Auvelity$123
- REXULTI$119
How this compares
$6,157 in reported general payments places this provider in the 85th percentile of 1,119 psychiatry providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Aripiprazole | 32 | $3,993 |
| Doxepin Hcl | 17 | $1,608 |
| Buspirone Hcl | 46 | $1,001 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 30 | $936 |
| Bupropion XlBupropion Hcl | 19 | $890 |
| Fluoxetine Hcl | 23 | $858 |
| Methylphenidate Hcl | 24 | $696 |
| Quetiapine Fumarate | 39 | $692 |
| Lamotrigine | 50 | $562 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 14 | $552 |
| Hydroxyzine Hcl | 28 | $478 |
| Trazodone Hcl | 51 | $444 |
| Olanzapine | 25 | $439 |
| Fluphenazine Hcl | 24 | $396 |
| Oxcarbazepine | 17 | $396 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Cleveland
- Binit ShahCleveland$913K
- Rajeet ShresthaCleveland$537K
- Martha SajatovicCleveland$404K
- Joseph CalabreseCleveland$82K
- Ketan DeorasCleveland$80K
- Keming GaoCleveland$76K
- Aaron VazquezCleveland$55K
- Shishuka MalhotraCanton$15M
- Henry NasrallahCincinnati$3.8M
- Otto DuenoDayton$3.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.